Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly
Caesar
2 other identifiers
interventional
194
1 country
2
Brief Summary
Alcohol misuse affects 5 million people in France. Even though the elderly are also concerned by this pathology, there is not much information about chronic alcohol misuse of this population in particular. Biological markers like gamma-glutamyltranspeptidase (GGT), mean corpuscular volume (MCV) and carbohydrate deficient transferrin (CDT) are usually used to detect alcohol abuse. As a biological marker of alcohol misuse, the specificity of the CDT is known to be superior to the GGT as well. However, when it comes to the elderly, alcoholism diagnosis tools are based on research of younger populations. This study aims to evaluate the benefit of the CDT to detect chronic alcohol use in the elderly.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2016
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2016
CompletedFirst Submitted
Initial submission to the registry
June 30, 2016
CompletedFirst Posted
Study publicly available on registry
July 6, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2016
CompletedNovember 20, 2025
November 1, 2016
7 months
June 30, 2016
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Benefit of Carbohydrate Deficient Transferrin to detect chronic alcohol abuse in the elderly compared to usual clinical detection tools
Analysis performed when at least 1 point at the AUDIT-C questionnaire, confirming presence of alcohol consumption
Within 3 days after enrollment in the study
Secondary Outcomes (5)
Sensitivity and specificity of the disturbance of Gamma-glutamyltranspeptidase when presence of alcohol consumption, with at least 1 point in the AUDIT-C questionnaire
Within 3 days after enrollment in the study
Sensitivity and specificity of the disturbance of Mean Corpuscular Volume when presence of alcohol consumption, with at least 1 point in the AUDIT-C questionnaire
Within 3 days after enrollment in the study
Socio-economic characteristics of alcohol abusers : Socioprofessional category
Within 3 days after enrollment in the study
Socio-economic characteristics of alcohol abusers : Education Category
Within 3 days after enrollment in the study
Socio-economic characteristics of alcohol abusers : Way of life
Within 3 days after enrollment in the study
Study Arms (1)
Alcohol Used Disorders Identification Test (AUDIT C)
OTHERSubmission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
Interventions
The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women.
Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
Eligibility Criteria
You may qualify if:
- At least 60 years old
- Patients hospitalized for a day or more in the Geriatrics Department of Mulhouse, GHRMSA :
- Coming from home within 48 hours after admission to the GHRMSA
- Study procedures performed within 72 hours after admission to the GHRMSA
- Or new members of the General Practitioner Support Association of Alsace, France (translated in French as the "RAG") living in Mulhouse, Thann and Saint Louis cities (France) :
- Living at home and joining the RAG between the 1st of March and the 31st of October 2016
- Study Procedures performed within 3 days after enrollment in the study
- Relative or helper available who usually visits the patient at home at least once a week
- Absence of alcoholic excipient in the concomitant medication
You may not qualify if:
- Age \< 60 years old
- Admitted in the Geriatrics Department of Mulhouse after more than 48hours after admission to the GHRMSA
- Presence of the following symptoms :
- Hepatobiliary deficiency related to a primary biliary cirrhosis
- Autoimmune or viral cirrhosis
- Hepatocellular carcinoma
- Congenital metabolic disorder in protein glycosylation
- Known genetics variance in Tf B or D transferrin
- Living in an elderly care institution
- Already enrolled in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Reseau d'Appui aux Generalistes (RAG)
Colmar, 68000, France
GHRMSA
Mulhouse, 68100, France
Related Publications (1)
Schnell C (2016) Benefit of carbohydrate deficient transferrin in detecting chronic alcohol abuse in the elderly: study protocol for a multicentre, non-randomized, open-label study. Clin Transl Degener Dis 1(3):121-126.
BACKGROUND
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cecile Schnell, MD
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2016
First Posted
July 6, 2016
Study Start
March 1, 2016
Primary Completion
October 1, 2016
Study Completion
October 1, 2016
Last Updated
November 20, 2025
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share